



HRI 2018 Phase 2 Inpatient Placebo-Controlled Double-Blind Acute Schizophrenia Results: **Separation Between Drug and Placebo!***

HRI Enrollment Achievement


- HRI RAND 20 study participants
- With 12 US sites, HRI tied with 5 other sites with highest RAND
- HRI had second highest number of Completers (n=17), beat by only one subject at another site

Study Results


- Study design used 1:1 active drug vs placebo
- Study showed that active drug significantly separated from placebo (p<0.0001)
- Sponsor moving to Phase 3 given the results

HRI Performance Success

- While HRI's data could not be analyzed for statistical significance given the low n, HRI's drug-placebo difference was slightly more than twice the average drug-placebo difference in the clinical trial
- Rater change comparing BSL to Primary Efficacy Visit occurred **ONLY** twice (11% of the time)



Sponsor Provided Data Points: PANSS Total Score By Treatment and Visit



*** Sponsor permitted HRI to share site results without sharing sponsor / study identity**